A Phase 4 interventional study of Luveris® 75 IU and Luveris® 25 IU in Hypogonadotropic Hypogonadism, sponsored by EMD Serono. Terminated at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.
Among the 185 studies in Hypogonadism with a site in United States, this one is the 135th largest by enrollment of the 154 interventional ones that give a count, is one of 15 that started in 2006, is one of 27 in phase 4, and was the 32nd registered.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
Browse Hypogonadism studies →12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:
Stephanie B. Seminara, MD · Sites in United States
Ages 18–45 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
Halozyme Therapeutics · Sites in United States
Ages 12–17 · Men only
Bradley Nindl · Sites in United States
Ages 18–40 · Healthy volunteers
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 62 · Phase 3 31 · Phase 4 27
First in 1989; this study’s year is marked. 15 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Median enrollment 45 across the 154 interventional studies, 70 across the 27 observational. Of the 154 that completed or were terminated, 84 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 185 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 3 studies filed under Hypogonadism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypogonadism with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04301765Seattle Institute for Biomedical and Clinical ResearchImproving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency | 2026-11 |
| NCT06720597University of California, IrvineEndoPAT Device for Endothelial Dysfunction in ED | 2027-01 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT06455969Bradley NindlAdaptions and Resiliency to Multi-Stressor OpeRations | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 185 studies in Hypogonadism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
To confirm the efficacy of the 75 IU dose of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of clinical pregnancy in women with hypogonadotropic hypogonadism and profound LH deficiency (LH \<1.2 IU/L), and to study the efficacy of a lower dose (25 IU) of Luveris® compared to placebo when administered concomitantly with follitropin alfa for induction of follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency (LH \<1.2 IU/L).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 weeks before initiation of treatment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Luveris® 75 IU · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)
Drug: Luveris® 25 IU · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)
Drug: Placebo · Drug: Recombinant human follicle stimulating hormone (r-hFSH) · Drug: Recombinant human chorionic gonadotropin (r-hCG)
Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Also known as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Also known as: Follitropin alfa
When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Also known as: Choriogonadotropin alfa
Time to Clinical Pregnancy
Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination.
Time frame: Stimulation Day 1 up to clinical pregnancy (Day 35-42 post r-hCG administration day [end of stimulation cycle {approximately 21 days}])
Percentage of Participants With Cumulative Clinical Pregnancy
Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination. Cumulative clinical pregnancy referred to all clinical pregnancy that occurred during all the 3 treatment cycles.
Time frame: Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days])
Percentage of Participants With Cumulative Ovulation
Ovulation was defined as a mid-luteal phase progesterone (P4) level greater than or equal to (\>=) 10 nanogram per milliliter (ng/mL). Cumulative ovulation referred to all ovulations that occurred during all the 3 treatment cycles.
Time frame: Recombinant human chorionic gonadotropin (r-hCG) administration day (end of stimulation cycle [approximately 21 days])
| Milestone | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| Started | 5 | 3 | 3 |
| Completed | 3 | 0 | 1 |
| Not completed | 2 | 3 | 2 |
| Withdrew: Pregnancy | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: In vitro fertilization treatment | 0 | 0 | 1 |
| Withdrew: Lack of ovarian response | 0 | 1 | 0 |
Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination.
| Days | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| Time to Clinical Pregnancy | 71 (47 to 116) | 51 (51 to 51) | 103 (103 to 103) |
Clinical pregnancy was defined as the presence of one or more fetal sac with fetal heart activity on the Day 35-42 post r-hCG ultrasound examination. Cumulative clinical pregnancy referred to all clinical pregnancy that occurred during all the 3 treatment cycles.
| Percentage of participants | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| Percentage of Participants With Cumulative Clinical Pregnancy | 60.0 | 33.3 | 33.3 |
Ovulation was defined as a mid-luteal phase progesterone (P4) level greater than or equal to (\>=) 10 nanogram per milliliter (ng/mL). Cumulative ovulation referred to all ovulations that occurred during all the 3 treatment cycles.
| Percentage of participants | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| Percentage of Participants With Cumulative Ovulation | 80.0 | 33.3 | 66.7 |
Collected over Stimulation Day 1 up to Day 35-42 post r-hCG administration day (end of stimulation cycle [approximately 21 days]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Luveris® 75 IU | — | 1/5 (20%) | 4/5 (80%) |
| Luveris® 25 IU | — | 0/3 (0%) | 1/3 (33.3%) |
| Placebo | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| Pneumonia pneumococcalInfections and infestations | 0/5 | 0/3 | 1/3 |
| Pneumonia streptococcalInfections and infestations | 0/5 | 0/3 | 1/3 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 1/5 | 0/3 | 0/3 |
| Event | Luveris® 75 IU | Luveris® 25 IU | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/5 | 1/3 | 2/3 |
| Abdominal distensionGastrointestinal disorders | 0/5 | 1/3 | 2/3 |
| Adnexa uteri painReproductive system and breast disorders | 3/5 | 0/3 | 0/3 |
| HeadacheNervous system disorders | 2/5 | 0/3 | 1/3 |
| Uterine spasmReproductive system and breast disorders | 2/5 | 0/3 | 1/3 |
| Ovarian cystReproductive system and breast disorders | 2/5 | 0/3 | 0/3 |
| Ligament sprainInjury, poisoning and procedural complications | 2/5 | 0/3 | 0/3 |
| DyspepsiaGastrointestinal disorders | 0/5 | 0/3 | 1/3 |
| DysstasiaNervous system disorders | 0/5 | 0/3 | 1/3 |
| MigraineNervous system disorders | 0/5 | 0/3 | 1/3 |
| Age Continuous(years) | Luveris® 75 IU | Luveris® 25 IU | Placebo | Total |
|---|---|---|---|---|
| Mean | 28.6 ± 2.5 | 34.3 ± 5.0 | 29.3 ± 3.8 | 30.4 ± 4.1 |
| Sex: Female, Male(Participants) | Luveris® 75 IU | Luveris® 25 IU | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 3 | 3 | 11 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2006, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutropin alfa